Abstract
Targeted therapies using nanoparticles have been proposed to address some drawbacks of conventional chemotherapy. In the last two decades, surface modification of nanoparticles with antibody ligands has been extensively explored for the safe and effective delivery of chemotherapeutic drugs. By capitalizing on receptors overexpressed on cancer cells or angiogenic endothelial cells, antibody-functionalized nanoparticles are promising candidates to improve selectivity for target cells and, thus, therapeutic efficacy.
This work offers a brief overview of nanotechnology applied to targeted cancer therapies and highlights the use of antibodies as targeting ligands. After presenting a summary of the most common methods for nanoparticle functionalization with antibodies, the authors discuss different targeting strategies divided into angiogenesis-associated targeting, uncontrolled cell proliferation targeting, and tumor cell targeting. Special emphasis is given to antibody-nanoparticle conjugates that have entered the clinical testing phase. Some explanations for the discrepancy between preclinical and clinical observations are also provided.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abedin MR, Powers K, Aiardo R, Barua D, Barua S (2021) Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Sci Rep 11(1):7347. https://doi.org/10.1038/s41598-021-86762-6
Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP (2013) Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. J Drug Target 21(10):994–1000. https://doi.org/10.3109/1061186x.2013.840639
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61(12):4750–4755
Aggarwal S, Yadav S, Gupta S (2011) EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed Nanotechnol 7(1):137–138. https://doi.org/10.1166/jbn.2011.1238
Aggarwal S, Gupta S, Pabla D, Murthy RS (2013) Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotechnol 4(6):145–157. https://doi.org/10.1007/s12645-013-0046-3
Ahn J, Miura Y, Yamada N, Chida T, Liu X, Kim A, Sato R, Tsumura R, Koga Y, Yasunaga M, Nishiyama N, Matsumura Y, Cabral H, Kataoka K (2015) Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials 39:23–30. https://doi.org/10.1016/j.biomaterials.2014.10.069
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763. https://doi.org/10.1038/nrc903
Amin M, Pourshohod A, Kheirollah A, Afrakhteh M, Gholami-Borujeni F, Zeinali M, Jamalan M (2018) Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes. J Drug Deliv Sci Technol 47:209–214. https://doi.org/10.1016/j.jddst.2018.07.017
Andrade F, Rafael D, Vilar-Hernández M, Montero S, Martínez-Trucharte F, Seras-Franzoso J, Díaz-Riascos ZV, Boullosa A, García-Aranda N, Cámara-Sánchez P, Arango D, Nestor M, Abasolo I, Sarmento B, Schwartz S (2021) Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo. J Control Release 331:198–212. https://doi.org/10.1016/j.jconrel.2021.01.022
Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H (2008) Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 19(12):2321–2331. https://doi.org/10.1021/bc8002452
Arya G, Vandana M, Acharya S, Sahoo SK (2011) Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomed Nanotechnol Biol Med 7(6):859–870. https://doi.org/10.1016/j.nano.2011.03.009
Ashrafzadeh MS, Akbarzadeh A, Heydarinasab A, Ardjmand M (2020) In vivo glioblastoma therapy using targeted liposomal cisplatin. Int J Nanomed 15:7035–7049. https://doi.org/10.2147/ijn.S255902
Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H (2007) In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 30(5):972–978. https://doi.org/10.1248/bpb.30.972
Aydın RS (2013) Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting. J Biomed Mater Res A 101(5):1405–1415. https://doi.org/10.1002/jbm.a.34448
Badkas A, Frank E, Zhou Z, Jafari M, Chandra H, Sriram V, Lee JY, Yadav JS (2018) Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin®-conjugated PLGA-PEG nanoparticles for drug delivery. Colloids Surf B Biointerfaces 162:271–278. https://doi.org/10.1016/j.colsurfb.2017.12.001
Bai MY, Liu SZ (2014) A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: an in vitro study of targeted delivery of cisplatin to ovarian cancer cells. Colloids Surf B Biointerfaces 117:346–353. https://doi.org/10.1016/j.colsurfb.2014.02.051
Barua S, Yoo JW, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S (2013) Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA 110(9):3270–3275. https://doi.org/10.1073/pnas.1216893110
Béduneau A, Saulnier P, Hindré F, Clavreul A, Leroux JC, Benoit JP (2007) Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments. Biomaterials 28(33):4978–4990. https://doi.org/10.1016/j.biomaterials.2007.05.014
Berger M, Shankar V, Vafai A (2002) Therapeutic applications of monoclonal antibodies. Am J Med Sci 324(1):14–30. https://doi.org/10.1097/00000441-200207000-00004
Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA (2010) Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol 396(5):1474–1490. https://doi.org/10.1016/j.jmb.2009.12.046
Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA (2017) Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine 13(1):263–273. https://doi.org/10.1016/j.nano.2016.08.017
Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7):1157–1164. https://doi.org/10.1016/0092-8674(94)90007-8
Burande AS, Viswanadh MK, Jha A, Mehata AK, Shaik A, Agrawal N, Poddar S, Mahto SK, Muthu MS (2020) EGFR targeted paclitaxel and piperine co-loaded liposomes for the treatment of triple negative breast cancer. AAPS PharmSciTech 21(5):151. https://doi.org/10.1208/s12249-020-01671-7
Bussard KM, Gigliotti CM, Adair BM, Snyder JM, Gigliotti NT, Loc WS, Wilczynski ZR, Liu ZK, Meisel K, Zemanek C, Mastro AM, Shupp AB, McGovern C, Matters GL, Adair JH (2021) Preferential uptake of antibody targeted calcium phosphosilicate nanoparticles by metastatic triple negative breast cancer cells in co-cultures of human metastatic breast cancer cells plus bone osteoblasts. Nanomedicine 34:102383. https://doi.org/10.1016/j.nano.2021.102383
Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615–1626. https://doi.org/10.1016/j.addr.2008.08.005
Castro A, Berois N, Malanga A, Ortega C, Oppezzo P, Pristch O, Mombrú AW, Osinaga E, Pardo H (2021) Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors. Int J Biol Macromol 182:806–814. https://doi.org/10.1016/j.ijbiomac.2021.04.054
Catania A, Barrajón-Catalán E, Nicolosi S, Cicirata F, Micol V (2013) Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res Treat 141(1):55–65. https://doi.org/10.1007/s10549-013-2667-y
Chen S, Florinas S, Teitgen A, Xu Z-Q, Gao C, Wu H, Kataoka K, Cabral H, Christie RJ (2017) Controlled Fab installation onto polymeric micelle nanoparticles for tuned bioactivity. Sci Technol Adv Mater 18(1):666–680. https://doi.org/10.1080/14686996.2017.1370361
Chen H, Lin J, Shan Y, Zhengmao L (2019) The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies. Biomed Pharmacother 115:108857. https://doi.org/10.1016/j.biopha.2019.108857
Chen R, Huang Y, Wang L, Zhou J, Tan Y, Peng C, Yang P, Peng W, Li J, Gu Q, Sheng Y, Wang Y, Shao G, Zhang Q, Sun Y (2021) Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. Biomater Sci 9(6):2279–2294. https://doi.org/10.1039/d0bm01904f
Chiu GN, Bally MB, Mayer LD (2003) Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1–2):115–121. https://doi.org/10.1016/s0005-2736(03)00142-1
Choi JS, Park JS (2017) Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells. Colloids Surf B Biointerfaces 159:139–150. https://doi.org/10.1016/j.colsurfb.2017.07.064
Choi JS, Jang WS, Park JS (2018) Comparison of adsorption and conjugation of Herceptin on poly(lactic-co-glycolic acid) nanoparticles – effect on cell internalization in breast cancer cells. Mater Sci Eng C Mater Biol Appl 92:496–507. https://doi.org/10.1016/j.msec.2018.06.059
Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F (2007) Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int J Pharm 331(2):190–196. https://doi.org/10.1016/j.ijpharm.2006.12.002
Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F (2009) Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 38(3):230–237. https://doi.org/10.1016/j.ejps.2009.07.006
Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F (2010) Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 144(3):324–331. https://doi.org/10.1016/j.jconrel.2010.02.026
Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S (2018) Half-chain cetuximab nanoconjugates allow multitarget therapy of triple negative breast cancer. Bioconjugate Chem 29(11):3817–3832. https://doi.org/10.1021/acs.bioconjchem.8b00667
Comparetti EJ, Romagnoli GG, Gorgulho CM, Pedrosa VA, Kaneno R (2020) Anti-PSMA monoclonal antibody increases the toxicity of paclitaxel carried by carbon nanotubes. Mater Sci Eng C Mater Biol Appl 116:111254. https://doi.org/10.1016/j.msec.2020.111254
Crivianu-Gaita V, Romaschin A, Thompson M (2015) High efficiency reduction capability for the formation of Fab' antibody fragments from F(ab)2 units. Biochem Biophys Rep 2:23–28. https://doi.org/10.1016/j.bbrep.2015.04.004
Dadashi Noshahr K, Shamsi F, Valtchev P, Kokhaei P, Hemati M, Reza Akbari Eidgahi M, Khaleghian A (2020) Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro. Saudi Pharm J 28(11):1392–1401. https://doi.org/10.1016/j.jsps.2020.09.003
Dai Q, Wilhelm S, Ding D, Syed AM, Sindhwani S, Zhang Y, Chen YY, MacMillan P, Chan WCW (2018) Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano 12(8):8423–8435. https://doi.org/10.1021/acsnano.8b03900
Dana P, Bunthot S, Suktham K, Surassmo S, Yata T, Namdee K, Yingmema W, Yimsoo T, Ruktanonchai UR, Sathornsumetee S, Saengkrit N (2020) Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. Colloids Surf B: Biointerfaces 196:111270. https://doi.org/10.1016/j.colsurfb.2020.111270
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006) The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121(2):144–158. https://doi.org/10.1016/j.clim.2006.06.010
Deepagan VG, Sarmento B, Menon D, Nascimento A, Jayasree A, Sreeranganathan M, Koyakutty M, Nair SV, Rangasamy J (2012) In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles. Nanomedicine (Lond) 7(4):507–519. https://doi.org/10.2217/nnm.11.139
Dewhirst MW, Secomb TW (2017) Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer 17(12):738–750. https://doi.org/10.1038/nrc.2017.93
Dienst A, Grunow A, Unruh M, Rabausch B, Nör JE, Fries JW, Gottstein C (2005) Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 97(10):733–747. https://doi.org/10.1093/jnci/dji130
Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M, Juárez J, Zepeda-Moreno A, del Toro-Arreola A, Topete A, Daneri-Navarro A (2019) Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf B Biointerfaces 178:199–207. https://doi.org/10.1016/j.colsurfb.2019.03.011
Dostalova S, Cerna T, Hynek D, Koudelkova Z, Vaculovic T, Kopel P, Hrabeta J, Heger Z, Vaculovicova M, Eckschlager T, Stiborova M, Adam V (2016) Site-directed conjugation of antibodies to apoferritin nanocarrier for targeted drug delivery to prostate cancer cells. ACS Appl Mater Interfaces 8(23):14430–14441. https://doi.org/10.1021/acsami.6b04286
Dostalova S, Polanska H, Svobodova M, Balvan J, Krystofova O, Haddad Y, Krizkova S, Masarik M, Eckschlager T, Stiborova M, Heger Z, Adam V (2018) Prostate-specific membrane antigen-targeted site-directed antibody-conjugated apoferritin nanovehicle favorably influences in vivo side effects of doxorubicin. Sci Rep 8(1):8867. https://doi.org/10.1038/s41598-018-26772-z
Duan D, Wang A, Ni L, Zhang L, Yan X, Jiang Y, Mu H, Wu Z, Sun K, Li Y (2018) Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Int J Nanomed 13:1831–1840. https://doi.org/10.2147/IJN.S153795
Eavarone DA, Yu X, Bellamkonda RV (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51(1):10–14. https://doi.org/10.1002/(sici)1097-4636(200007)51:1<10::aid-jbm2>3.0.co;2-r
Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ (2017a) Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anticancer Agents Med Chem 17(1):48–56
Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM (2017b) Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eur J Pharm Biopharm 115:159–167. https://doi.org/10.1016/j.ejpb.2017.02.020
Eloy JO, Ruiz A, de Lima FT, Petrilli R, Raspantini G, Nogueira KAB, Santos E, de Oliveira CS, Borges JC, Marchetti JM, Al-Jamal WT, Chorilli M (2020) EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. Colloids Surf B Biointerfaces 194:111185. https://doi.org/10.1016/j.colsurfb.2020.111185
Engelberg S, Modrejewski J, Walter JG, Livney YD, Assaraf YG (2018) Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles. Oncotarget 9(30):20993–21006. https://doi.org/10.18632/oncotarget.24772
Fang J, Nakamura H, Maeda H (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136–151. https://doi.org/10.1016/j.addr.2010.04.009
Fathian Kolahkaj F, Derakhshandeh K, Khaleseh F, Azandaryani AH, Mansouri K, Khazaei M (2019) Active targeting carrier for breast cancer treatment: Monoclonal antibody conjugated epirubicin loaded nanoparticle. J Drug Deliv Sci Technol 53:101136. https://doi.org/10.1016/j.jddst.2019.101136
Fay F, McLaughlin KM, Small DM, Fennell DA, Johnston PG, Longley DB, Scott CJ (2011) Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 32(33):8645–8653. https://doi.org/10.1016/j.biomaterials.2011.07.065
Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992) Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 89(6):2018–2022. https://doi.org/10.1172/jci115811
Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, Martins G, Barros A, Santos LL, Sarmento B, Ferreira JA (2019) Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm 570:118646. https://doi.org/10.1016/j.ijpharm.2019.118646
Fu Q, Wang J, Liu H (2020) Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles. Drug Deliv 27(1):1535–1543. https://doi.org/10.1080/10717544.2020.1837294
Gan H, Chen L, Sui X, Wu B, Zou S, Li A, Zhang Y, Liu X, Wang D, Cai S, Liu X, Liang Y, Tang X (2018) Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma. Mater Sci Eng C Mater Biol Appl 91:395–403. https://doi.org/10.1016/j.msec.2018.05.011
Gao X, Luo Y, Wang Y, Pang J, Liao C, Lu H, Fang Y (2012) Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy. Int J Nanomedicine 7:4037–4051. https://doi.org/10.2147/ijn.S32804
Gao J, Xia Y, Chen H, Yu Y, Song J, Li W, Qian W, Wang H, Dai J, Guo Y (2014) Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond) 9(2):279–293. https://doi.org/10.2217/nnm.13.20
Gao Y, Li Y, Li Y, Yuan L, Zhou Y, Li J, Zhao L, Zhang C, Li X, Liu Y (2015) PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking. Nanoscale 7(2):597–612. https://doi.org/10.1039/C4NR05738D
Gosk S, Moos T, Gottstein C, Bendas G (2008) VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 1778(4):854–863. https://doi.org/10.1016/j.bbamem.2007.12.021
Greene MK, Richards DA, Nogueira JCF, Campbell K, Smyth P, Fernández M, Scott CJ, Chudasama V (2018) Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments. Chem Sci 9(1):79–87. https://doi.org/10.1039/C7SC02747H
Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC (2007) Targeted nanoparticles for cancer therapy. Nano Today 2(3):14–21. https://doi.org/10.1016/S1748-0132(07)70083-X
Guo S, Zhang Y, Wu Z, Zhang L, He D, Li X, Wang Z (2019) Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin. Biomed Pharmacother 118:109225. https://doi.org/10.1016/j.biopha.2019.109225
Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2(3):256–265. https://doi.org/10.4161/mabs.2.3.11641
Hariri W, Sudha T, Bharali DJ, Cui H, Mousa SA (2015) Nano-targeted delivery of toremifene, an estrogen receptor-α blocker in prostate cancer. Pharm Res 32(8):2764–2774. https://doi.org/10.1007/s11095-015-1662-x
Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H (2007) Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 342(1–2):194–200. https://doi.org/10.1016/j.ijpharm.2007.04.037
He H, Liu L, Morin EE, Liu M, Schwendeman A (2019) Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures. Acc Chem Res 52(9):2445–2461. https://doi.org/10.1021/acs.accounts.9b00228
Hu CM, Kaushal S, Tran Cao HS, Aryal S, Sartor M, Esener S, Bouvet M, Zhang L (2010) Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm 7(3):914–920. https://doi.org/10.1021/mp900316a
Huang WT, Larsson M, Wang YJ, Chiou SH, Lin HY, Liu DM (2015) Demethoxycurcumin-carrying chitosan-antibody core-shell nanoparticles with multitherapeutic efficacy toward malignant A549 lung tumor: from in vitro characterization to in vivo evaluation. Mol Pharm 12(4):1242–1249. https://doi.org/10.1021/mp500747w
Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19(4 Suppl 3):7–16
Jain A, Cheng K (2017) The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J Control Release 245:27–40. https://doi.org/10.1016/j.jconrel.2016.11.016
Jain S, Deore SV, Ghadi R, Chaudhari D, Kuche K, Katiyar SS (2021) Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. Mater Sci Eng C Mater Biol Appl 121:111832. https://doi.org/10.1016/j.msec.2020.111832
Jin C, Qian N, Zhao W, Yang W, Bai L, Wu H, Wang M, Song W, Dou K (2010) Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. Biomacromolecules 11(9):2422–2431. https://doi.org/10.1021/bm1005992
Jin C, Yang Z, Yang J, Li H, He Y, An J, Bai L, Dou K (2013) Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. J Nanopart Res 16(1):2157. https://doi.org/10.1007/s11051-013-2157-5
Johnston MC, Nicoll JA, Redmond KM, Smyth P, Greene MK, McDaid WJ, Chan DKW, Crawford N, Stott KJ, Fox JP, Straubinger NL, Roche S, Clynes M, Straubinger RM, Longley DB, Scott CJ (2020) DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. J Control Release 324:610–619. https://doi.org/10.1016/j.jconrel.2020.05.046
Karra N, Nassar T, Ripin AN, Schwob O, Borlak J, Benita S (2013) Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small 9(24):4221–4236. https://doi.org/10.1002/smll.201301417
Kennedy PJ, Sousa F, Ferreira D, Pereira C, Nestor M, Oliveira C, Granja PL, Sarmento B (2018) Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. Acta Biomater 81:208–218. https://doi.org/10.1016/j.actbio.2018.09.043
Khaleseh F, Hemmati Azandaryani A, Fathian Kolahkaj F, Khazaei M, Derakhshandeh K (2021) Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. IET Nanobiotechnol 15(3):257–265. https://doi.org/10.1049/nbt2.12012
Khanna V, Kalscheuer S, Kirtane A, Zhang W, Panyam J (2019) Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Future Drug Discov 1(1):Fdd8. https://doi.org/10.4155/fdd-2019-0005
Khayrani AC, Mahmud H, Oo AKK, Zahra MH, Oze M, Du J, Alam MJ, Afify SM, Quora HAA, Shigehiro T, Calle AS, Okada N, Seno A, Fujita K, Hamada H, Seno Y, Mandai T, Seno M (2019) Targeting ovarian cancer cells overexpressing CD44 with immunoliposomes encapsulating glycosylated paclitaxel. Int J Mol Sci 20(5). https://doi.org/10.3390/ijms20051042
Kholodenko RV, Kalinovsky DV, Doronin II, Ponomarev ED, Kholodenko IV (2019) Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations. Curr Med Chem 26(3):396–426. https://doi.org/10.2174/0929867324666170817152554
Kim IY, Kang YS, Lee DS, Park HJ, Choi EK, Oh YK, Son HJ, Kim JS (2009) Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 140(1):55–60. https://doi.org/10.1016/j.jconrel.2009.07.005
Kim JH, Kim Y, Bae KH, Park TG, Lee JH, Park K (2015a) Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. Mol Pharm 12(4):1230–1241. https://doi.org/10.1021/mp500737y
Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH (2015b) Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett 369(1):250–258. https://doi.org/10.1016/j.canlet.2015.08.022
Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120(1-2):18–26. https://doi.org/10.1016/j.jconrel.2007.03.012
Kolhar P, Anselmo AC, Gupta V, Pant K, Prabhakarpandian B, Ruoslahti E, Mitragotri S (2013) Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci USA 110(26):10753. https://doi.org/10.1073/pnas.1308345110
Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N (2004) Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 108(2):301–306. https://doi.org/10.1002/ijc.11526
Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F (2011) Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6:1903–1912. https://doi.org/10.2147/ijn.S23211
Kou G, Gao J, Wang H, Chen H, Li B, Zhang D, Wang S, Hou S, Qian W, Dai J, Zhong Y, Guo Y (2007) Preparation and Characterization of Paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J Biochem Mol Biol 40(5):731–739. https://doi.org/10.5483/bmbrep.2007.40.5.731
Kouchakzadeh H, Shojaosadati SA, Tahmasebi F, Shokri F (2013) Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles. Int J Pharm 447(1):62–69. https://doi.org/10.1016/j.ijpharm.2013.02.043
Kuesters GM, Campbell RB (2010) Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine (Lond) 5(2):181–192. https://doi.org/10.2217/nnm.09.105
Kulhari H, Pooja D, Shrivastava S, Kuncha M, Naidu VGM, Bansal V, Sistla R, Adams DJ (2016) Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep 6(1):23179. https://doi.org/10.1038/srep23179
Kullberg M, Mann K, Anchordoquy TJ (2012) Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol Pharm 9(7):2000–2008. https://doi.org/10.1021/mp300049n
Kumar S, Li C (2001) Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 22(3):129. https://doi.org/10.1016/S1471-4906(00)01840-8
Kumar Mehata A, Bharti S, Singh P, Viswanadh MK, Kumari L, Agrawal P, Singh S, Koch B, Muthu MS (2019) Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. Colloids Surf B Biointerfaces 173:366–377. https://doi.org/10.1016/j.colsurfb.2018.10.007
Kuo YC, Chao IW (2016) Conjugation of melanotransferrin antibody on solid lipid nanoparticles for mediating brain cancer malignancy. Biotechnol Prog 32(2):480–490. https://doi.org/10.1002/btpr.2214
Kutty RV, Feng SS (2013) Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials 34(38):10160–10171. https://doi.org/10.1016/j.biomaterials.2013.09.043
Kutty RV, Chia SL, Setyawati MI, Muthu MS, Feng SS, Leong DT (2015) In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer. Biomaterials 63:58–69. https://doi.org/10.1016/j.biomaterials.2015.06.005
Laskin JJ, Sandler AB (2004) Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30(1):1–17. https://doi.org/10.1016/j.ctrv.2003.10.002
Leung SL, Zha Z, Cohn C, Dai Z, Wu X (2014) Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells. Colloids Surf B Biointerfaces 121:141–149. https://doi.org/10.1016/j.colsurfb.2014.06.011
Li N, Xie X, Hu Y, He H, Fu X, Fang T, Li C (2019) Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am J Transl Res 11(3):1255–1269
Lim KH, Huang H, Pralle A, Park S (2011) Engineered streptavidin monomer and dimer with improved stability and function. Biochemistry 50(40):8682–8691. https://doi.org/10.1021/bi2010366
Limasale YD, Tezcaner A, Özen C, Keskin D, Banerjee S (2015) Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. Int J Pharm 479(2):364–373. https://doi.org/10.1016/j.ijpharm.2015.01.016
Lin C, Wong BCK, Chen H, Bian Z, Zhang G, Zhang X, Kashif Riaz M, Tyagi D, Lin G, Zhang Y, Wang J, Lu A, Yang Z (2017) Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep 7(1):1097. https://doi.org/10.1038/s41598-017-00957-4
Lin WW, Cheng YA, Li CC, Ho KW, Chen HJ, Chen IU, Huang BC, Liu HJ, Lu YC, Cheng CM, Huang MY, Lai HW, Cheng TL (2021) Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Sci Rep 11(1):7598. https://doi.org/10.1038/s41598-021-87271-2
Liszbinski RB, Romagnoli GG, Gorgulho CM, Basso CR, Pedrosa VA, Kaneno R (2020) Anti-EGFR-coated gold nanoparticles in vitro carry 5-fluorouracil to colorectal cancer cells. Materials (Basel) 13(2). https://doi.org/10.3390/ma13020375
Liu Y, Feng SS (2011) The synergistic effect of herceptin and docetaxel in polylactide-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles. J Control Release 152:e64–e65. https://doi.org/10.1016/j.jconrel.2011.08.125
Liu P, Li Z, Zhu M, Sun Y, Li Y, Wang H, Duan Y (2010) Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J Mater Sci Mater Med 21(2):551–556. https://doi.org/10.1007/s10856-009-3925-8
Liu KC, Arivajiagane A, Wu SJ, Tzou SC, Chen CY, Wang YM (2019) Development of a novel thermal-sensitive multifunctional liposome with antibody conjugation to target EGFR-expressing tumors. Nanomedicine 15(1):285–294. https://doi.org/10.1016/j.nano.2018.10.006
Logie J, Ganesh AN, Aman AM, Al-awar RS, Shoichet MS (2017) Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model. Biomaterials 123:39–47. https://doi.org/10.1016/j.biomaterials.2017.01.026
Lourenço BN, Pereira RF, Barrias CC, Fischbach C, Oliveira C, Granja PL (2021) Engineering modular half-antibody conjugated nanoparticles for targeting CD44v6-expressing cancer cells. Nanomaterials (Basel) 11(2). https://doi.org/10.3390/nano11020295
Lu R-M, Chang Y-L, Chen M-S, Wu H-C (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32(12):3265–3274. https://doi.org/10.1016/j.biomaterials.2010.12.061
Lu X, Liu S, Han M, Yang X, Sun K, Wang H, Mu H, Du Y, Wang A, Ni L, Zhang C (2019) Afatinib-loaded immunoliposomes functionalized with cetuximab: a novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. Int J Pharm 560:126–135. https://doi.org/10.1016/j.ijpharm.2019.02.001
Ma X, Cheng Z, Jin Y, Liang X, Yang X, Dai Z, Tian J (2014) SM5-1-Conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy. Biomaterials 35(9):2878–2889. https://doi.org/10.1016/j.biomaterials.2013.12.045
Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65(24):11631–11638. https://doi.org/10.1158/0008-5472.Can-05-1093
Marques AC, Costa PJ, Velho S, Amaral MH (2020) Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release 320:180–200. https://doi.org/10.1016/j.jconrel.2020.01.035
Marques AC, Costa PJ, Velho S, Amaral MH (2021) Stimuli-responsive hydrogels for intratumoral drug delivery. Drug Discov Today. https://doi.org/10.1016/j.drudis.2021.04.012
Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15(3):517–525. https://doi.org/10.1093/annonc/mdh092
Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi Y (2014) Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomedicine 9:1855–1870. https://doi.org/10.2147/ijn.S51880
Matusewicz L, Podkalicka J, Sikorski AF (2018) Immunoliposomes with simvastatin as a potential therapeutic in treatment of breast cancer cells overexpressing HER2-an in vitro study. Cancers 10(11). https://doi.org/10.3390/cancers10110418
Matusewicz L, Filip-Psurska B, Psurski M, Tabaczar S, Podkalicka J, Wietrzyk J, Ziółkowski P, Czogalla A, Sikorski AF (2019) EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. Int J Pharm 569:118605. https://doi.org/10.1016/j.ijpharm.2019.118605
Maya S, Kumar LG, Sarmento B, Sanoj Rejinold N, Menon D, Nair SV, Jayakumar R (2013) Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym 93(2):661–669. https://doi.org/10.1016/j.carbpol.2012.12.032
Maya S, Sarmento B, Lakshmanan VK, Menon D, Jayakumar R (2014a) Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells. J Biomed Nanotechnol 10(8):1416–1428. https://doi.org/10.1166/jbn.2014.1841
Maya S, Sarmento B, Lakshmanan VK, Menon D, Seabra V, Jayakumar R (2014b) Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells. Int J Biol Macromol 69:532–541. https://doi.org/10.1016/j.ijbiomac.2014.06.009
Maya S, Uthaman S, Sarmento B, Mohan CG, Park IK, Jayakumar R (2017) In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts. Int J Nanomedicine 12:7165–7182. https://doi.org/10.2147/ijn.S143529
McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, Scott CJ (2008) Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem 19(8):1561–1569. https://doi.org/10.1021/bc800057g
Meng LX, Ren Q, Meng Q, Zheng YX, He ML, Sun SY, Ding ZJ, Li BC, Wang HY (2018) Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. Artif Cells Nanomed Biotechnol 46(sup3):S556–s563. https://doi.org/10.1080/21691401.2018.1501380
Mi Y, Huang Y, Deng J (2018) The enhanced delivery of salinomycin to CD133(+) ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles. Oncol Lett 15(5):6611–6621. https://doi.org/10.3892/ol.2018.8140
Mitri Z, Constantine T, O'Regan R (2012) The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193. https://doi.org/10.1155/2012/743193
Mondal L, Mukherjee B, Das K, Bhattacharya S, Dutta D, Chakraborty S, Pal MM, Gaonkar RH, Debnath MC (2019) CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice. Int J Nanomedicine 14:8073–8094. https://doi.org/10.2147/ijn.S220740
Mozafarinia M, Karimi S, Farrokhnia M, Esfandiari J (2021) In vitro breast cancer targeting using Trastuzumab-conjugated mesoporous silica nanoparticles: towards the new strategy for decreasing size and high drug loading capacity for drug delivery purposes in MSN synthesis. Microporous Mesoporous Mat 316:110950. https://doi.org/10.1016/j.micromeso.2021.110950
Nagesh PKB, Johnson NR, Boya VKN, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, Jaggi M, Yallapu MM (2016) PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces 144:8–20. https://doi.org/10.1016/j.colsurfb.2016.03.071
Nakamura Y, Mochida A, Choyke PL, Kobayashi H (2016) Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem 27(10):2225–2238. https://doi.org/10.1021/acs.bioconjchem.6b00437
Navarro-Marchal SA, Griñán-Lisón C, Entrena JM, Ruiz-Alcalá G, Tristán-Manzano M, Martin F, Pérez-Victoria I, Peula-García JM, Marchal JA (2021) Anti-CD44-conjugated olive oil liquid nanocapsules for targeting pancreatic cancer stem cells. Biomacromolecules 22(4):1374–1388. https://doi.org/10.1021/acs.biomac.0c01546
Nichols JW, Bae YH (2014) EPR: evidence and fallacy. J Control Release 190:451–464. https://doi.org/10.1016/j.jconrel.2014.03.057
Ning ST, Lee SY, Wei MF, Peng CL, Lin SY, Tsai MH, Lee PC, Shih YH, Lin CY, Luo TY, Shieh MJ (2016) Targeting colorectal cancer stem-like cells with Anti-CD133 antibody-conjugated SN-38 nanoparticles. ACS Appl Mater Interfaces 8(28):17793–17804. https://doi.org/10.1021/acsami.6b04403
Niu G, Chen X (2010) Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11(8):1000–1017. https://doi.org/10.2174/138945010791591395
Niza E, Noblejas-López MDM, Bravo I, Nieto-Jiménez C, Castro-Osma JA, Canales-Vázquez J, Lara-Sanchez A, Galán Moya EM, Burgos M, Ocaña A, Alonso-Moreno C (2019) Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast cancer. Nanomaterials 9(12). https://doi.org/10.3390/nano9121793
Noh JK, Naeem M, Cao J, Lee EH, Kim MS, Jung Y, Yoo JW (2016) Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells. Int J Pharm 513(1-2):543–553. https://doi.org/10.1016/j.ijpharm.2016.09.067
Notabi MK, Arnspang EC, Andersen MØ (2021) Antibody conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic pharmaceuticals. Eur J Pharm Sci 161:105777. https://doi.org/10.1016/j.ejps.2021.105777
Oliveira C, Gonçalves CS, Martins EP, Neves NM, Reis RL, Costa BM, Silva TH, Martins A (2021) Fucoidan/chitosan nanoparticles functionalized with anti-ErbB-2 target breast cancer cells and impair tumor growth in vivo. Int J Pharm 600:120548. https://doi.org/10.1016/j.ijpharm.2021.120548
Owiti AO, Pal D, Mitra A (2018) PSMA antibody-conjugated pentablock copolymer nanomicellar formulation for targeted delivery to prostate cancer. AAPS PharmSciTech 19(8):3534–3549. https://doi.org/10.1208/s12249-018-1126-9
Öztürk K, Esendağlı G, Gürbüz MU, Tülü M, Çalış S (2017) Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. Int J Pharm 517(1-2):157–167. https://doi.org/10.1016/j.ijpharm.2016.12.009
Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A (2018) Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul 35(2):204–217. https://doi.org/10.1080/02652048.2018.1453560
Peng XH, Wang Y, Huang D, Wang Y, Shin HJ, Chen Z, Spewak MB, Mao H, Wang X, Wang Y, Chen ZG, Nie S, Shin DM (2011) Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano 5(12):9480–9493. https://doi.org/10.1021/nn202410f
Peng J, Chen J, Xie F, Bao W, Xu H, Wang H, Xu Y, Du Z (2019) Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer. Biomaterials 222:119420. https://doi.org/10.1016/j.biomaterials.2019.119420
Perche F, Patel NR, Torchilin VP (2012) Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release 164(1):95–102. https://doi.org/10.1016/j.jconrel.2012.09.003
Pereira I, Sousa F, Kennedy P, Sarmento B (2018) Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells. Int J Pharm 549(1–2):397–403. https://doi.org/10.1016/j.ijpharm.2018.08.016
Petrilli R, Eloy JO, Saggioro FP, Chesca DL, de Souza MC, Dias MVS, da Silva LLP, Lee RJ, Lopez RFV (2018) Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release 283:151–162. https://doi.org/10.1016/j.jconrel.2018.05.038
Pindiprolu S, Krishnamurthy PT, Dev C, Chintamaneni PK (2021) DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Chem Phys Lipids 235:105033. https://doi.org/10.1016/j.chemphyslip.2020.105033
Qi T, Shi Y, Huang Y, Fu X, Qiu S, Sun Q, Lin G (2020) The role of antibody delivery formation in cancer therapy. J Drug Target 28(6):574–584. https://doi.org/10.1080/1061186x.2020.1728537
Qian C, Wang Y, Chen Y, Zeng L, Zhang Q, Shuai X, Huang K (2013) Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials 34(26):6175–6184. https://doi.org/10.1016/j.biomaterials.2013.04.056
Qiu W, Zhang H, Chen X, Song L, Cui W, Ren S, Wang Y, Guo K, Li D, Chen R, Wang Z (2019) A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. Nanomedicine (Lond) 14(17):2339–2353. https://doi.org/10.2217/nnm-2019-0063
Qu C, Li J, Zhou Y, Yang S, Chen W, Li F, You B, Liu Y, Zhang X (2018) Targeted delivery of doxorubicin via CD147-mediated ROS/pH dual-sensitive nanomicelles for the efficient therapy of hepatocellular carcinoma. AAPS J 20(2):34. https://doi.org/10.1208/s12248-018-0195-8
Raju A, Muthu MS, Feng SS (2013) Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv 10(6):747–760. https://doi.org/10.1517/17425247.2013.777425
Ramalho MJ, Sevin E, Gosselet F, Lima J, Coelho MAN, Loureiro JA, Pereira MC (2018) Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm 545(1):84–92. https://doi.org/10.1016/j.ijpharm.2018.04.062
Richards DA, Maruani A, Chudasama V (2017) Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem Sci 8(1):63–77. https://doi.org/10.1039/C6SC02403C
Rodallec A, Sicard G, Giacometti S, Carré M, Pourroy B, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R (2018) From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. Int J Nanomedicine 13:6677–6688. https://doi.org/10.2147/ijn.S179290
Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R (2020a) Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anticancer Drugs 31(5):463–472. https://doi.org/10.1097/cad.0000000000000878
Rodallec A, Franco C, Robert S, Sicard G, Giacometti S, Lacarelle B, Bouquet F, Savina A, Lacroix R, Dignat-George F, Ciccolini J, Poncelet P, Fanciullino R (2020b) Prototyping trastuzumab docetaxel immunoliposomes with a new FCM-based method to quantify optimal antibody density on nanoparticles. Sci Rep 10(1):4147. https://doi.org/10.1038/s41598-020-60856-z
Sabra R, Billa N, Roberts CJ (2019) Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. Int J Pharm 572:118775. https://doi.org/10.1016/j.ijpharm.2019.118775
Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62(24):7190
Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW (2008) Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. J Drug Target 16(7):601–604. https://doi.org/10.1080/10611860802228954
Scavo MP, Cutrignelli A, Depalo N, Fanizza E, Laquintana V, Gasparini G, Giannelli G, Denora N (2020) Effectiveness of a controlled 5-FU delivery based on FZD10 antibody-conjugated liposomes in colorectal cancer in vitro models. Pharmaceutics 12(7). https://doi.org/10.3390/pharmaceutics12070650
Schmid D, Fay F, Small DM, Jaworski J, Riley JS, Tegazzini D, Fenning C, Jones DS, Johnston PG, Longley DB, Scott CJ (2014) Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. Mol Ther 22(12):2083–2092. https://doi.org/10.1038/mt.2014.137
Schnyder A, Krähenbühl S, Drewe J, Huwyler J (2005) Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 13(5):325–335. https://doi.org/10.1080/10611860500206674
Schroeder HW Jr, Cavacini L (2010) Structure and function of immunoglobulins. J Allergy Clin Immunol 125(2 Suppl 2):S41–S52. https://doi.org/10.1016/j.jaci.2009.09.046
Shein SA, Kuznetsov II, Abakumova TO, Chelushkin PS, Melnikov PA, Korchagina AA, Bychkov DA, Seregina IF, Bolshov MA, Kabanov AV, Chekhonin VP, Nukolova NV (2016) VEGF- and VEGFR2-targeted liposomes for cisplatin delivery to glioma cells. Mol Pharm 13(11):3712–3723. https://doi.org/10.1021/acs.molpharmaceut.6b00519
Shen J, Cai W, Ma Y, Xu R, Huo Z, Song L, Qiu X, Zhang Y, Li A, Cao W, Zhou S, Tang X (2020) hGC33-modified and sorafenib-loaded nanoparticles have a synergistic anti-hepatoma effect by inhibiting Wnt signaling pathway. Nanoscale Res Lett 15(1):220. https://doi.org/10.1186/s11671-020-03451-5
Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20–37. https://doi.org/10.1038/nrc.2016.108
Siddhartha VT, Pindiprolu S, Chintamaneni PK, Tummala S, Nandha Kumar S (2018) RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies. Artif Cells Nanomed Biotechnol 46(2):387–397. https://doi.org/10.1080/21691401.2017.1313267
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
Son S, Shin S, Rao NV, Um W, Jeon J, Ko H, Deepagan VG, Kwon S, Lee JY, Park JH (2018) Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Int J Biol Macromol 110:406–415. https://doi.org/10.1016/j.ijbiomac.2017.10.113
Souto EB, Doktorovova S, Campos JR, Martins-Lopes P, Silva AM (2019) Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells. Eur J Pharm Sci 128:27–35. https://doi.org/10.1016/j.ejps.2018.11.022
Steichen SD, Caldorera-Moore M, Peppas NA (2013) A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 48(3):416–427. https://doi.org/10.1016/j.ejps.2012.12.006
Steinhauser I, Spänkuch B, Strebhardt K, Langer K (2006) Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials 27(28):4975–4983. https://doi.org/10.1016/j.biomaterials.2006.05.016
Sumer Bolu B, Golba B, Sanyal A, Sanyal R (2020) Trastuzumab targeted micellar delivery of docetaxel using dendron–polymer conjugates. Biomater Sci 8(9):2600–2610. https://doi.org/10.1039/C9BM01764J
Sun B, Feng SS (2009) Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) 4(4):431–445. https://doi.org/10.2217/nnm.09.17
Sun B, Ranganathan B, Feng SS (2008) Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29(4):475–486. https://doi.org/10.1016/j.biomaterials.2007.09.038
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Suryo Rahmanto Y, Bal S, Loh KH, Yu Y, Richardson DR (2012) Melanotransferrin: search for a function. Biochim Biophys Acta 1820(3):237–243. https://doi.org/10.1016/j.bbagen.2011.09.003
Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171(3):280–287. https://doi.org/10.1016/j.jconrel.2013.07.014
Taheri A, Dinarvand R, Atyabi F, Ghahremani MH, Ostad SN (2012) Trastuzumab decorated methotrexate–human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur J Pharm Sci 47(2):331–340. https://doi.org/10.1016/j.ejps.2012.06.016
Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, Jiang Z, Liu X, Liang Y, Ma D (2018) Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv 25(1):1484–1494. https://doi.org/10.1080/10717544.2018.1477859
Thorek DL, Elias DR, Tsourkas A (2009) Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry. Mol Imaging 8(4):221–229
Tian H, Huang Y, He J, Zhang M, Ni P (2021) CD147 Monoclonal antibody targeted reduction-responsive camptothecin polyphosphoester nanomedicine for drug delivery in hepatocellular carcinoma cells. ACS Appl Bio Mater 4(5):4422–4431. https://doi.org/10.1021/acsabm.1c00177
Tummala S, Gowthamarajan K, Satish Kumar MN, Wadhwani A (2016a) Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors. Drug Deliv 23(5):1773–1787. https://doi.org/10.3109/10717544.2015.1084400
Tummala S, Kumar MN, Pindiprolu SK (2016b) Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles. Drug Deliv 23(9):3505–3519. https://doi.org/10.1080/10717544.2016.1199606
van der Steen SC, Raavé R, Langerak S, van Houdt L, van Duijnhoven SM, van Lith SA, Massuger LF, Daamen WF, Leenders WP, van Kuppevelt TH (2017) Targeting the extracellular matrix of ovarian cancer using functionalized, drug loaded lyophilisomes. Eur J Pharm Biopharm 113:229–239. https://doi.org/10.1016/j.ejpb.2016.12.010
Van Hoesen K, Meynier S, Ribaux P, Petignat P, Delie F, Cohen M (2017) Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system? Oncotarget 8(63):107176–107187. https://doi.org/10.18632/oncotarget.22412
Varshosaz J, Davoudi MA, Rasoul-Amini S (2018) Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. J Liposome Res 28(4):285–295. https://doi.org/10.1080/08982104.2017.1370471
Vauquelin G, Charlton SJ (2013) Exploring avidity: Understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168(8):1771–1785. https://doi.org/10.1111/bph.12106
Vedakumari SW, Senthil R, Sekar S, Babu CS, Sastry TP (2019) Enhancing anti-cancer activity of erlotinib by antibody conjugated nanofibrin – In vitro studies on lung adenocarcinoma cell lines. Mater Chem Phys 224:328–333. https://doi.org/10.1016/j.matchemphys.2018.11.061
Vihinen P, Ala-aho R, Kähäri VM (2005) Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5(3):203–220. https://doi.org/10.2174/1568009053765799
Viswanadh MK, Vikas JA, Reddy Adena SK, Mehata AK, Priya V, Neogi K, Poddar S, Mahto SK, Muthu MS (2020) Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. Nanomedicine (Lond) 15(24):2345–2367. https://doi.org/10.2217/nnm-2020-0167
Vivek R, Thangam R, NipunBabu V, Rejeeth C, Sivasubramanian S, Gunasekaran P, Muthuchelian K, Kannan S (2014) Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. ACS Appl Mater Interfaces 6(9):6469–6480. https://doi.org/10.1021/am406012g
Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M (2005) Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells–a potential tool for specific drug delivery. Pharm Res 22(11):1906–1917. https://doi.org/10.1007/s11095-005-7247-3
Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J Jr, Schwartz D, Kreuter J, von Briesen H, Langer K (2010) Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31(8):2388–2398. https://doi.org/10.1016/j.biomaterials.2009.11.093
Wang XB, Zhou HY (2015) Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer. Biomed Pharmacother 70:123–128. https://doi.org/10.1016/j.biopha.2015.01.008
Wang L, Su W, Liu Z, Zhou M, Chen S, Chen Y, Lu D, Liu Y, Fan Y, Zheng Y, Han Z, Kong D, Wu JC, Xiang R, Li Z (2012) CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 33(20):5107–5114. https://doi.org/10.1016/j.biomaterials.2012.03.067
Wang X, Liu Y, Wang S, Shi D, Zhou X, Wang C, Wu J, Zeng Z, Li Y, Sun J, Wang J, Zhang L, Teng Z, Lu G (2015) CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer. Appl Surf Sci 332:308–317. https://doi.org/10.1016/j.apsusc.2015.01.204
Wang JK, Zhou YY, Guo SJ, Wang YY, Nie CJ, Wang HL, Wang JL, Zhao Y, Li XY, Chen XJ (2017) Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy. Mater Sci Eng C Mater Biol Appl 76:944–950. https://doi.org/10.1016/j.msec.2017.03.131
Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B, Wei L, Gao J, Zhou W (2018) Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes. Nanomedicine 14(6):1949–1961. https://doi.org/10.1016/j.nano.2017.09.012
Wang M, Liu W, Zhang Y, Dang M, Zhang Y, Tao J, Chen K, Peng X, Teng Z (2019) Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer. J Colloid Interface Sci 538:630–637. https://doi.org/10.1016/j.jcis.2018.12.032
Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K (2004) Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12(7):461–471. https://doi.org/10.1080/10611860400010697
Wei J, Sun J, Liu Y (2019) Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies. Oncol Lett 17(4):4024–4033. https://doi.org/10.3892/ol.2019.10050
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–157. https://doi.org/10.1016/j.jconrel.2014.12.030
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW (2016) Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1(5):16014. https://doi.org/10.1038/natrevmats.2016.14
Wong BC, Zhang H, Qin L, Chen H, Fang C, Lu A, Yang Z (2014) Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Drug Des Devel Ther 8:993–1001. https://doi.org/10.2147/dddt.S63235
Wu ST, Fowler AJ, Garmon CB, Fessler AB, Ogle JD, Grover KR, Allen BC, Williams CD, Zhou R, Yazdanifar M, Ogle CA, Mukherjee P (2018) Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer 18(1):457. https://doi.org/10.1186/s12885-018-4393-7
Xiong XY, Guo L, Gong YC, Li ZL, Li YP, Liu ZY, Zhou M (2012) In vitro & in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin–avidin interaction. Eur J Pharm Sci 46(5):537–544. https://doi.org/10.1016/j.ejps.2012.04.011
Xiong J, Han S, Ding S, He J, Zhang H (2018) Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Oncol Rep 39(3):1396–1404. https://doi.org/10.3892/or.2018.6201
Xu S, Cui F, Huang D, Zhang D, Zhu A, Sun X, Cao Y, Ding S, Wang Y, Gao E, Zhang F (2019) PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. Int J Nanomedicine 14:17–32. https://doi.org/10.2147/ijn.S175340
Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC (2010) Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 3:11. https://doi.org/10.1186/1757-2215-3-11
Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, Chauhan SC (2014) Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35(30):8635–8648. https://doi.org/10.1016/j.biomaterials.2014.06.040
Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD (2007) Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24(12):2402–2411. https://doi.org/10.1007/s11095-007-9425-y
Yang W, Hu Q, Xu Y, Liu H, Zhong L (2018) Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C Mater Biol Appl 89:328–335. https://doi.org/10.1016/j.msec.2018.04.011
Yin XB, Wu LQ, Huang MW, Zhou F, Wang K, Yu X, Wang KY, Fu HQ (2014a) Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity. Biomed Pharmacother 68(5):597–602. https://doi.org/10.1016/j.biopha.2014.04.006
Yin XB, Wu LQ, Fu HQ, Huang MW, Wang K, Zhou F, Yu X, Wang KY (2014b) Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies. Asian Pac J Trop Med 7(5):337–343. https://doi.org/10.1016/s1995-7645(14)60052-3
Youn YS, Bae YH (2018) Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Deliv Rev 130:3–11. https://doi.org/10.1016/j.addr.2018.05.008
Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R (2011) Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine 6:1977–1990. https://doi.org/10.2147/ijn.S21523
Yu K, Zhao J, Zhang Z, Gao Y, Zhou Y, Teng L, Li Y (2016a) Enhanced delivery of paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Int J Pharm 497(1):78–87. https://doi.org/10.1016/j.ijpharm.2015.11.033
Yu K, Zhou Y, Li Y, Sun X, Sun F, Wang X, Mu H, Li J, Liu X, Teng L, Li Y (2016b) Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles. Biomater Sci 4(8):1219–1232. https://doi.org/10.1039/C6BM00308G
Yu J, Hu F, Zhu Q, Li X, Ren H, Fan S, Qian B, Zhai B, Yang D (2020) PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. Nanoscale Res Lett 15(1):59. https://doi.org/10.1186/s11671-019-3228-z
Zalba S, Contreras AM, Haeri A, ten Hagen TLM, Navarro I, Koning G, Garrido MJ (2015) Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release 210:26–38. https://doi.org/10.1016/j.jconrel.2015.05.271
Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, Ratcliffe J, Scoble JA, Drummond CJ, Tran N (2018) Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl Mater Interfaces 10(30):25174–25185. https://doi.org/10.1021/acsami.8b08125
Zhang X, Liu J, Li X, Li F, Lee RJ, Sun F, Li Y, Liu Z, Teng L (2019) Trastuzumab-coated nanoparticles loaded with docetaxel for breast cancer therapy. Dose Response 17(3):1559325819872583. https://doi.org/10.1177/1559325819872583
Zhao J, Feng SS (2014) Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs. Biomaterials 35(10):3340–3347. https://doi.org/10.1016/j.biomaterials.2014.01.003
Zhao L, Li H, Shi Y, Wang G, Liu L, Su C, Su R (2015) Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. Int J Nanomedicine 10:245–256. https://doi.org/10.2147/ijn.S74868
Zhong S, Ling Z, Zhou Z, He J, Ran H, Wang Z, Zhang Q, Song W, Zhang Y, Luo J (2020) Herceptin-decorated paclitaxel-loaded poly(lactide-co-glycolide) nanobubbles: ultrasound-facilitated release and targeted accumulation in breast cancers. Pharm Dev Technol 25(4):454–463. https://doi.org/10.1080/10837450.2019.1709500
Zhou Z, Badkas A, Stevenson M, Lee JY, Leung YK (2015) Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. Int J Pharm 487(1-2):81–90. https://doi.org/10.1016/j.ijpharm.2015.03.081
Zhu R, Zhang CG, Liu Y, Yuan ZQ, Chen WL, Yang SD, Li JZ, Zhu WJ, Zhou XF, You BG, Zhang XN (2015) CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with alpha-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells. Sci Rep 5:17904. https://doi.org/10.1038/srep17904
Zhu R, Wang Z, Liang P, He X, Zhuang X, Huang R, Wang M, Wang Q, Qian Y, Wang S (2017) Efficient VEGF targeting delivery of DOX using bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy. Acta Biomater 63:163–180. https://doi.org/10.1016/j.actbio.2017.09.009
Acknowledgments
This work was financed by national funds from FCT - Fundação para a Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB. Ana Camila Marques gratefully acknowledges FCT for financial support (grant reference: 2020.06766.BD).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Marques, A.C., da Costa, P.C., Velho, S., Amaral, M.H. (2023). Antibody-Functionalized Nanoparticles for Targeted Drug Delivery in Cancer Therapy. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_297-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_297-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences